- Conditions
- End Stage Renal Disease
- Interventions
- there is no intervention
- Other
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 150 participants
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 874
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Migraine Disorders, Chronic Migraine Headache, Migraine
- Interventions
- Middle Meningeal Artery Embolization
- Procedure
- Lead sponsor
- Cortex Neurovascular
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Clinical Observation, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
- Procedure · Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Electronic Health Record Review
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Asthma
- Interventions
- Mepolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 13 more
- Conditions
- Pompe Disease
- Interventions
- Rituximab, Miglustat
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Glaucoma Patients, Retina Patients, Eyes With Corneal Abnormality, Normal Healthy Eyes
- Interventions
- This is an observational study only, all patients are imaged on the investigational device
- Device
- Lead sponsor
- Intalight, Inc
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • New York, New York • Houston, Texas
- Conditions
- Breast Cancer Detection, Dense Breast Parenchyma, Benign Breast Findings, Normal Breast Screening, Abnormal Breast Screening
- Interventions
- Reading of Automated Breast Ultrasound in conjunction with Screening Mammography
- Device
- Lead sponsor
- Delphinus Medical Technologies, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
- Interventions
- Observational Cohort (No Intervention)
- Other
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Atlanta, Georgia • Houston, Texas
- Conditions
- Alzheimer Disease
- Interventions
- PET-MR Scan, PiB
- Procedure · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pelvic Organ Prolapse, Stress Urinary Incontinence
- Interventions
- Observational only
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
- Interventions
- Olipudase alfa
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- Up to 2 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio + 3 more
- Conditions
- Congenital Heart Disease
- Interventions
- Somascan 5.0
- Diagnostic Test
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 2 Days to 5 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Opioid Overdose
- Interventions
- Observation only
- Other
- Lead sponsor
- Member Companies of the Opioid PMR Consortium
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 808,455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Wilmington, Delaware • Boston, Massachusetts • Portland, Oregon + 1 more
- Conditions
- Alzheimer Disease
- Interventions
- Donanemab, Usual Care
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 6,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 1
- States / cities
- Huntsville, Alabama
- Conditions
- Radiation Retinopathy
- Interventions
- Fluocinolone Acetonide (FA) implant
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Brain and Nervous System
- Interventions
- Not listed
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 1 Year to 30 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Amblyopia
- Interventions
- Not listed
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 3 Years to 6 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Postoperative Cognitive Complications, Delirium, Perioperative/Postoperative Complications, Brain Injuries, Anesthesia
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Schizophrenia
- Interventions
- Placebo, RO5545965, risperidone
- Other · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Heart Failure, Congestive
- Interventions
- No intervention - observational study only
- Other
- Lead sponsor
- Brian Hiestand MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Uterine Fibroids (UF)
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Arlington, Virginia
- Conditions
- Fever
- Interventions
- IV Placebo, IV Acetaminophen, Reference Standard Endotoxin (RSE)
- Drug · Biological
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Austin, Texas